Natixis Advisors LLC Has $533,000 Position in PetIQ, Inc. (NASDAQ:PETQ)

Natixis Advisors LLC lifted its position in shares of PetIQ, Inc. (NASDAQ:PETQ) by 103.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,171 shares of the company’s stock after buying an additional 12,315 shares during the period. Natixis Advisors LLC owned about 0.08% of PetIQ worth $533,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of PetIQ by 4.9% during the first quarter. Vanguard Group Inc. now owns 2,252,842 shares of the company’s stock worth $41,182,000 after buying an additional 105,083 shares during the period. Dimensional Fund Advisors LP boosted its position in PetIQ by 13.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,086,625 shares of the company’s stock valued at $21,461,000 after purchasing an additional 132,450 shares during the last quarter. Boston Partners boosted its position in PetIQ by 6.8% during the first quarter. Boston Partners now owns 1,067,677 shares of the company’s stock valued at $19,124,000 after purchasing an additional 67,797 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in PetIQ by 11.7% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,036,292 shares of the company’s stock valued at $20,467,000 after purchasing an additional 108,870 shares during the last quarter. Finally, Nepsis Inc. boosted its position in PetIQ by 0.4% during the second quarter. Nepsis Inc. now owns 901,425 shares of the company’s stock valued at $19,885,000 after purchasing an additional 3,256 shares during the last quarter. 94.99% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. William Blair cut PetIQ from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 7th. Truist Financial cut PetIQ from a “buy” rating to a “hold” rating and increased their price target for the company from $30.00 to $31.00 in a research report on Thursday, August 8th. Two equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.67.

PetIQ Stock Performance

PETQ opened at $30.66 on Friday. PetIQ, Inc. has a 12-month low of $15.09 and a 12-month high of $30.77. The stock has a market cap of $912.20 million, a price-to-earnings ratio of 139.36 and a beta of 1.73. The business has a 50 day moving average of $26.48 and a 200-day moving average of $21.49. The company has a quick ratio of 1.68, a current ratio of 2.58 and a debt-to-equity ratio of 1.68.

PetIQ (NASDAQ:PETQ) last released its quarterly earnings results on Wednesday, August 7th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.50 by $0.20. The business had revenue of $328.90 million during the quarter, compared to analysts’ expectations of $330.14 million. PetIQ had a return on equity of 18.75% and a net margin of 1.20%. The firm’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same period last year, the firm posted $0.37 EPS. On average, equities research analysts expect that PetIQ, Inc. will post 1.05 earnings per share for the current year.

PetIQ Company Profile

PetIQ, Inc operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which sells flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as third-party branded products for dogs and cats.